| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29.
|
| [2] |
王理伟，陈栋晖．从《胰腺癌综合诊治中国专家共识(2014)》发布看中国胰腺癌的规范化综合诊治[J]．浙江医学，2014(13):1125-1126, 1136.
|
| [3] |
刘凤永，王茂强，段峰，等．胰腺癌肝转移的介入治疗[J]．中国肿瘤临床，2012, 39(6): 331-335.
|
| [4] |
Ito K, Govindarajan A, Ito H, et al. Surgical treatment of hepatic colorectal metastasis: evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century[J]. Cancer J, 2010, 16(2):103-110.
|
| [5] |
Mayo SC, Herman JM, Cosgrove D, et al. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies[J]. J Am Coll Surg, 2013, 216(1):123-134.
|
| [6] |
Takada T, Yasuda H, Amano H, et al. Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma:does it improve survival?[J]. Hepatogastroenterology, 1997, 44(14):567-573.
|
| [7] |
Gleisner AL, Assumpcao L, Cameron JL, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?[J]. Cancer, 2007, 110(11):2484-2492.
|
| [8] |
de Jong MC, Tsai S, Cameron JL, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis[J]. J Surg Oncol, 2010, 102(3):256-263.
|
| [9] |
Seelig SK, Burkert B, Chromik AM, et al. Pancreatic resections for advanced M1-pancreatic carcinoma: the value of synchronous metastasectomy[J]. HPB Surg, 2010:579672.
|
| [10] |
Klein F, Puhl G, Guckelberger O, et al. The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma[J]. Gastroenterol Res Pract, 2012:939350.
|
| [11] |
Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma[J]. Ann Surg Oncol, 2007, 14(1):118-127.
|
| [12] |
Dünschede F, Will L, von Langsdorf C, et al. Treatment of metachronous and simultaneous liver metastases of pancreatic cancer[J]. Eur Surg Res, 2010, 44(3/4):209-213.
|
| [13] |
Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1, 452 patients and development of a prognostic model[J]. Ann Surg, 2006, 244(4):524-535.
|
| [14] |
Michalski CW, Erkan M, Hüser N, et al. Resection of primary pancreatic cancer and liver metastasis: a systematic review[J]. Dig Surg, 2008, 25(6):473-480.
|
| [15] |
Zanini N, Lombardi R, Masetti M, et al. Surgery for isolated liver metastases from pancreatic cancer[J]. Updates Surg, 2015, 67(1):19-25.
|
| [16] |
Azizi A, Naguib NN, Mbalisike E, et al. Liver metastases of pancreatic cancer: role of repetitive transarterial chemoembolization (TACE) on tumor response and survival[J]. Pancreas, 2011, 40(8):1271-1275.
|
| [17] |
Tajima H, Ohta T, Kitagawa H, et al. Pilot study of hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for patients with postoperative liver metastases from pancreatic cancer[J]. Exp Ther Med, 2011, 2(2):265-269.
|
| [18] |
De Jong MC, Farnell MB, Sclabas G, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis[J]. Ann Surg, 2010, 252(1):142-148.
|
| [19] |
Wiley AL Jr, Wirtanen GW, Mehta MP, et al. Treatment of probable subclinical liver metastases and gross pancreatic carcinoma with hepatic artery 5-fluorouracil infusion and radiation therapy[J]. Acta Oncol, 1988, 27(4):377-381.
|
| [20] |
Bydder S, Spry NA, Christie DR, et al. A prospective trial of short-fractionation radiotherapy for the palliation of liver metastases[J]. Australas Radiol, 2003, 47(3):284-288.
|
| [21] |
Goodman KA, Wiegner EA, Maturen KE, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies[J]. Int J Radiat Oncol Biol Phys, 2010, 78(2):486-493.
|
| [22] |
Zhang SY, Zhu GY, Li G, et al. Application of stereotactic body radiation therapy to cancer liver metastasis[J]. Cancer lett, 2016, 379(2):225-229.
|
| [23] |
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364(19):1817-1825.
|
| [24] |
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369(18):1691-1703.
|
| [25] |
Zhang DS, Wang DS, Wang ZQ, et al. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer[J]. Cancer Chemother Pharmacol, 2013, 71(4):1065-1072.
|
| [26] |
李晓青，钱家鸣．《2015年美国国立综合癌症网络胰腺癌临床实践指南(V2版)》更新要点及临床路径[J]．临床肝胆病杂志，2015(5):649-653.
|
| [27] |
Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study[J]. J Clin Oncol, 2013, 31(13):1640-1648.
|
| [28] |
Li Y, Sun J, Jiang Z, et al. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia[J]. J Chemother, 2015, 27(4):227-234.
|
| [29] |
中国临床肿瘤学会胰腺癌专家委员会．胰腺癌综合诊治中国专家共识(2014年版)[J]．临床肝胆病杂志，2014(4):358-370.
|
| [30] |
Sun JD, Liu Q, Wang J, et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer[J]. Clin Cancer Res, 2012, 18(3):758-770.
|
| [31] |
Van Cutsem E, Lenz HJ, Furuse J, et al. Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: primary analysis of the randomized, double-blind phase III MAESTRO study[J]. J Clin Oncol, 2016, 34(4 suppl 1):193.
|
| [32] |
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25(15):1960-1966.
|
| [33] |
Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer[J]. J Clin Oncol, 2009, 27(13):2231-2237.
|
| [34] |
Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer[J]. Science, 2009, 324(5933):1457-1461.
|
| [35] |
Catenacci DV, Junttila MR, Karrison T, et al. Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a Hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer[J]. J Clin Oncol, 2015, 33(36):4284-4292.
|
| [36] |
Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer[J]. J Clin Oncol, 2015, 33(12):1325-1333.
|
| [37] |
Le DT, Brockstedt DG, Nir-Paz R, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction[J]. Clin Cancer Res, 2012, 18(3):858-868.
|
| [38] |
Haage A, Schneider IC. Cellular contractility and extracellular matrix stiffness regulate matrix metalloproteinase activity in pancreatic cancer cells[J]. FASEB J, 2014, 28(8):3589-3599.
|
| [39] |
Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer[J]. Gut, 2013, 62(1):112-120.
|
| [40] |
Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial[J]. J Clin Oncol, 2011, 29(34):4548-4554.
|